✦ LIBER ✦

804 IMMEDIATE OR DEFERRED ANDROGEN DEPRIVATION FOR PATIENTS WITH PROSTATE CANCER AND NO LOCAL TREATMENT OF THE PROSTATE: LONG TERM RESULTS OF EORTC 30891

✍ Scribed by U.E. Studer; P. Whelan; W. Albrecht; F. Wimpissinger; J. Casselman; Th.M. De Reijke; T. Sulser; S. Madersbacher; S. Isorna; S.K. Sundaram; L. Collette

Book ID: 119623142
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 201 KB
Volume: 10
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(11)60791-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

354 LONG TERM RESULTS OF IMMEDIATE VERSU

354 LONG TERM RESULTS OF IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRI-VATION IN PATIENTS WITH NO LOCAL TREATMENT FOR T0–4 N0–2 M0 PROSTATE CANCER (EORTC 30891)

✍ Studer, Urs; Whelan, Peter; Albrecht, Walter; Wimpissinger, Florian; Casselman, 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 176 KB

Immediate or Deferred Androgen Deprivati

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

✍ Kibel, A.S.; Andriole, G.L. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 57 KB

Re: Immediate or Deferred Androgen Depri

Re: Immediate or Deferred Androgen Deprivation for Patients with Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

✍ Cesare Selli 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 52 KB

19 WHICH SUBGROUPS OF PATIENTS WITH NEWL

19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO-2 MO PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT (EORTC 30891) ARE AT RISK TO DIE FROM PROSTATE CANCER AND BENEFIT FROM IMMEDIATE ANDROGEN DEPRIVATION?

✍ U.E. Studer; L. Collette; P. Whelan; W. Albrecht; J. Casselman; T. De Reijke; H. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 318 KB

Differences in Time to Disease Progressi

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12Years of Follow-up

✍ Kibel, A.S. 📂 Article 📅 2014 🏛 Elsevier Science ⚖ 46 KB

Using PSA to Guide Timing of Androgen De

Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)

✍ Urs E. Studer; Laurence Collette; Peter Whelan; Walter Albrecht; Jacques Casselm 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 757 KB